Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist"

Circulation. 2018 Aug 7;138(6):660-661. doi: 10.1161/CIRCULATIONAHA.118.035717.

Authors

David R Matthews¹, Vlado Perkovic², Kenneth W Mahaffey³

Affiliations

¹ Oxford Centre for Diabetes, Endocrinology, and Metabolism and Harris Manchester College, Oxford, UK (D.R.M.).
² The George Institute for Global Health, University of New South Wales Sydney, Australia (V.P.).
³ Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, CA (K.W.M.).

PMID: 30354619
DOI: 10.1161/CIRCULATIONAHA.118.035717

No abstract available

Publication types

Letter
Comment

MeSH terms

Canagliflozin
Cardiovascular Diseases*
Glucose
Humans
Sodium
Sodium-Glucose Transporter 2 Inhibitors*

Substances

Sodium-Glucose Transporter 2 Inhibitors
Canagliflozin
Sodium
Glucose